Exozymes Inc. (EXOZ) stock
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.31−0.68 (-17.04%)
Close on Nov 17, 2026Market cap $30.72MP/E –Yield –
Exozymes cash
Cash and short-term investments held at the end of each period.
Exozymes's cash was $3.26M at Sep 30, 2026. For fiscal 2025 it was $3.04M, down 68.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04M | -68.7% |
| FY2024 | Dec 31, 2024 | $9.72M | +14508.3% |
| FY2023 | Dec 31, 2023 | $66.53K | -88.1% |
| FY2022 | Dec 31, 2022 | $558.57K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.26M | -36.1% |
| Q2 FY2026 | Jun 30, 2026 | $5.65M | -19.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.44M | -83.0% |
| Q4 FY2025 | Dec 31, 2025 | $3.04M | -68.7% |
| Q3 FY2025 | Sep 30, 2025 | $5.10M | +2079.5% |
| Q2 FY2025 | Jun 30, 2025 | $6.99M | +4314.8% |
| Q1 FY2025 | Mar 31, 2025 | $8.51M | +7379.6% |
| Q4 FY2024 | Dec 31, 2024 | $9.72M | +14508.3% |
| Q3 FY2024 | Sep 30, 2024 | $233.94K | -50.7% |
| Q2 FY2024 | Jun 30, 2024 | $158.24K | -71.7% |
| Q1 FY2024 | Mar 31, 2024 | $113.80K | – |
| Q4 FY2023 | Dec 31, 2023 | $66.53K | – |
| Q3 FY2023 | Sep 30, 2023 | $474.56K | – |
| Q4 FY2022 | Dec 31, 2022 | $558.57K | – |
See a number that looks wrong?